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ABSTRACT Trichomoniasis is the most prevalent curable sexually transmitted dis-
ease (STD). It has been associated with preterm birth and the acquisition and trans-
mission of HIV. Recently, nucleic acid ampliﬁcation tests (NAAT) have been FDA
cleared in the United States for detection of Trichomonas vaginalis in specimens
from both women and men. This study reports the results of a multicenter study re-
cently conducted using the Xpert TV (T. vaginalis) assay to test specimens from both
men and women. On-demand results were available in as little as 40 min for posi-
tive specimens. A total of 1,867 women and 4,791 men were eligible for inclusion in
the analysis. In women, the performance of the Xpert TV assay was compared to the
patient infected status (PIS) derived from the results of InPouch TV broth culture
and Aptima NAAT for T. vaginalis. The diagnostic sensitivities and speciﬁcities of the
Xpert TV assay for the combined female specimens (urine samples, self-collected
vaginal swabs, and endocervical swabs) ranged from 99.5 to 100% and 99.4 to
99.9%, respectively. For male urine samples, the diagnostic sensitivity and speciﬁcity
were 97.2% and 99.9%, respectively, compared to PIS results derived from the re-
sults of broth culture for T. vaginalis and bidirectional gene sequencing of ampli-
cons. Excellent performance characteristics were seen using both female and male
specimens. The ease of using the Xpert TV assay should result in opportunities for
enhanced screening for T. vaginalis in both men and women and, hopefully, im-
proved control of this infection.
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Trichomonas vaginalis is a ﬂagellated protozoan parasite that causes genitourinaryinfections in women and men. It is the most prevalent curable sexually transmitted
disease (STD) and is easily treated with inexpensive antibiotics (1, 2). Trichomoniasis
causes distressing symptoms like vaginal discharge and irritation in women and
urethritis in men (3, 4). It is also signiﬁcantly associated with an increased risk of
preterm birth and the acquisition and transmission of STDs, including HIV, as well as
being associated with infertility (5–8). Currently, however, there is no national control
program for this infection. Until recently, the tests available for detection of the parasite
were relatively insensitive (direct microscopy and antigen detection) or not widely
available (culture) (9, 10). The advent and FDA clearance of nucleic acid ampliﬁcation
tests (NAAT) for diagnosis of T. vaginalis in women (urine [UR] samples, endocervical
swab [ES] specimens, vaginal swab [VS] specimens, and patient-collected vaginal swab
[PC-VS] specimens) has greatly improved our diagnostic capability, but until now there
was no FDA-cleared test for detection of T. vaginalis in male urine samples (11). The
GeneXpert system (Cepheid, Sunnyvale, CA) is already used to diagnose other STDs,
such as Neisseria gonorrhoeae and Chlamydia trachomatis (12). We now report on the
performance of this assay for the detection of T. vaginalis in specimens from women
and men.
MATERIALS AND METHODS
This multicenter study evaluated test performance in prospectively collected ﬁrst-catch urine (UR)
samples from both women and men, endocervical swab (ES) specimens, clinician-collected vaginal swab
(CC-VS) specimens, and patient-collected vaginal swab (PC-VS) specimens in a clinical setting. The sites
participating in this study were academic medical centers, STD clinics, family planning clinics, public
health departments, and clinical trial ofﬁces. The sites were located across the United States, including
the West Coast, the Midwest, Southern states, and the East Coast. Subjects were eligible for enrollment
regardless of the presence or absence of genital symptoms. Seventeen diverse geographic sites partic-
ipated in collection of the specimens. Institutional Review Board approval was obtained for each of the
collection sites.
To be eligible for study enrollment, participants needed to be sexually active, 14 years of age, and
provide informed consent and minor assent if needed. Subjects were excluded if they had been
previously enrolled in the study, had received antimicrobial therapy within 21 days prior to enrollment,
had undergone a hysterectomy, or had urinated less than 1 h prior to specimen collection. Female study
participants were classiﬁed as symptomatic if they reported any of the following symptoms: itching,
burning, redness, soreness, or irritation of the genitals, unusual odor, abnormal vaginal discharge, coital
pain, and/or dysuria. Males were classiﬁed as symptomatic if they reported any of the following signs
and/or symptoms: urethral discharge, dysuria, or urethral itching or burning, burning after ejaculation,
and/or dysuria. Study participants not reporting any of the above symptoms were classiﬁed as asymp-
tomatic.
The following samples were collected from females: one PC-VS specimen (collected in a clinical
setting) for testing by the Xpert TV assay, followed by two CC-VS specimens for testing by the InPouch
TV culture-based method (BioMed Diagnostics, White City, OR) and the Aptima TV NAAT (Hologic,
Bedford, MA) (specimens alternated), three ES specimens (the ﬁrst swab for InPouch, while the second
and third swabs were alternated for Aptima and Xpert assays), and 35 to 50 ml of ﬁrst-catch UR for
InPouch, Xpert, and Aptima assays. For males, 35 to 50 ml of ﬁrst-catch UR was collected for InPouch
testing, bidirectional gene sequencing of amplicons, and Xpert testing. For “collection only” participating
sites, the specimens designated for Xpert testing and reference assay testing were shipped to designated
testing laboratories on the same day as collection whenever possible. All Xpert testing was performed
within 72 h of collection.
Assay procedures. Each trial specimen was collected by using the Cepheid specimen collection
device (swab or urine) and tested with the Xpert TV assay. Transport reagent containing the specimen
was gently inverted 3 to 4 times, followed by transferring 0.5 ml of the sample to the Xpert cartridge
using the transfer pipet supplied. Aptima assay testing was performed according to the manufacturer’s
package insert. For InPouch testing, CC-VS and ES specimens were inoculated at the collection site. For
UR cultures with the InPouch assay, 10 to 15 ml of the urine specimen was centrifuged at 500  g for
5 min and the sediment inoculated into the culture pouch on-site within 1 h of collection. Culture
pouches were shipped to the reference testing laboratory within 24 h of collection, with receipt of
specimens occurring within 48 h of collection. These specimens were shipped at ambient temperature
with two warming packs per shipping box. At the reference laboratory, cultures were incubated at 37°C
and read daily on weekdays for 3 days to look for the presence of motile protozoans with characteristic
morphology according to the InPouch package insert instructions.
The results of the reference tests (InPouch and Aptima for female specimens and InPouch and a
validated sequencing method [bidirectional amplicon sequencing of the excess urine remaining from
Xpert testing for male specimens]) were used to determine the patient infected status (PIS). The PIS was
used to designate a subject as infected or not infected. The subject was considered infected if either of
the reference test results were positive for T. vaginalis, while the subject was considered not infected
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when both reference test results were negative for T. vaginalis. Bidirectional nucleic acid sequencing was
performed on specimens from women with discrepant results between Xpert testing and PIS, as well as
an equal number of specimens from women who were determined to be uninfected (i.e., true negatives).
For male specimens, secondary sequencing was performed on any specimens with discrepant results
between Xpert testing and PIS. Quality control for the Xpert TV assay consisted of one T. vaginalis-
negative and one T. vaginalis-positive external control, with both controls being run on each day that
study specimens were tested. Study specimens were not run until valid test results were obtained for
both the negative and positive controls. Additionally, several internal controls are built-in to the assay to
monitor all aspects of the analytical process with each specimen run, including a sample processing
control (SPC), a sample adequacy control (SAC), and a probe check control (PCC). The SPC is present to
control for adequate processing of the target trichomonads and to monitor the presence of inhibitors in
the PCR. The SAC reagents are included to detect the presence of a single-copy human gene and monitor
whether the specimen contains human cells. The PCC veriﬁes reagent rehydration, PCR tube ﬁlling in the
cartridge, probe integrity, and dye stability. Only those study specimens with valid control results
available for all study test methods were included in the data analyses.
Statistical analyses were performed using SAS.
RESULTS
Results for female subjects. A total of 1,876 female subjects were initially enrolled
in this clinical study, 1,867 (99.5%) of whom were eligible for inclusion. The nine
ineligible subjects consisted of three subjects with a history of hysterectomy, two
subjects with improper or incomplete informed consent, two subjects previously
enrolled in the study, and two subjects who had been treated with antibiotics within
the 21 days prior to study enrollment. Of the 1,867 eligible study participants, 714
(38.2%) were symptomatic and 1,153 (61.8%) were asymptomatic. The average age
among eligible study participants was 33.5 years (range, 18 to 78 years).
From the 1,867 eligible female study subjects, 1,799 (96.4%) ES, 1,791 (95.9%) PC-VS,
and 1,793 (96.0%) UR specimens were included in the ﬁnal data set. The reasons for
exclusion of each specimen type are shown in Fig. 1.
The Xpert TV (T. vaginalis) assay successfully produced results for 98.4% (5,306/
5,391) of the samples from eligible female subjects on the ﬁrst attempt. The 85
FIG 1 Specimen accountability for specimens from eligible female and male participants. Ref, reference.
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indeterminate results included 74 ERROR readouts (test failed, possibly because the
reaction tube was ﬁlled improperly, a reagent probe integrity problem was detected,
pressure limits were exceeded, or a valve positioning error was detected), 2 NO RESULT
readouts (test was aborted), and 9 INVALID readouts (the SPC [sample processing
control] and/or the SAC [sample adequacy control] failed—the sample was not properly
processed, PCR was inhibited, or the sample was not properly collected). Eighty-three
of the 85 indeterminate cases were retested; two samples were not retested. Seventy-
seven of 83 indeterminate cases retested yielded valid results upon repeat assay. The
overall rate of assay success was 99.9% (5,383/5,391).
Overall, relative to the patient infected status (PIS) results, the Xpert TV assay
demonstrated initial sensitivity and speciﬁcity values of 98.4% and 99.7%, respectively,
for urine samples, 98.9% and 98.9%, respectively, for endocervical swab specimens, and
96.4% and 99.6%, respectively, for patient-collected vaginal swab specimens (Table 1).
There were no statistically signiﬁcant differences in performance with respect to
symptomatic status (Table 2).
Homogeneity analysis by site indicated that the results across sites were poolable
for speciﬁcity. For diagnostic sensitivity, female ES specimens demonstrated nonho-
mogeneity; however, the overall sensitivity was high (99.5%), with all sites but one
having 100% sensitivity. The one site with less than 100% sensitivity demonstrated a
sensitivity of 83.3% ([10/12], 95% conﬁdence interval [CI] 51.6% to 97.9%). Though the





tested Sensitivity 95% CI Speciﬁcity 95% CI % prevalence PPV (%) NPV (%)
ES InPouch 1,799 98.7 (153/155) 95.4–99.8 97.6 (1,604/1,644) 96.7–98.3 8.6 89.3 99.9
Aptima 1,799 100 (175/175) 98.3–99.3 98.9 (1,606/1,624) 98.3–99.3 9.7 90.7 100
PIS 1,799 98.9 (175/177) 96.0–99.9 98.9 (1,604/1,622) 98.3–99.3 9.8 90.7 99.9
PC-VS InPouch 1,791 96.9 (156/161) 92.9–99.0 97.7 (1,593/1,630) 96.9–98.4 9.0 80.8. 99.7
Aptima 1,791 97.4 (186/191) 94.0–99.1 99.6 (1,593/1,600) 99.1–998 10.7 96.4 99.7
PIS 1,791 96.4 (186/193) 92.7–98.5 99.6 (1,591/1,598) 99.1–99.8 10.8 96.4 99.6
UR InPouch 1,793 97.7 (148/150) 95.3–99.8 97.7 (1,606/1,643) 96.9–98.4 8.4 80.0 99.9
Aptima 1,793 99.4 (178/179) 96.9–100 99.6 (1,607/1,614) 99.1–99.8 10.0 96.2 99.9
PIS 1,793 98.4 (180/183) 95.3–99.7 99.7 (1,605/1,610) 99.3–99.9 10.2 97.3 99.8
aValues in parentheses are the number of true positives over the total of true positives plus false negatives (sensitivity) and the number of true negatives over the
total of true negatives plus false positives (speciﬁcity). PIS, patient infected status (see Materials and Methods); PPV, positive predictive value; NPV, negative predictive
value; ES, endocervical swab; PC-VS, patient-collected vaginal swab; UR, urine.
TABLE 2 Xpert TV versus PIS results by symptomatic status for femalesa
Sample type Status No. tested Sensitivity 95% CI Speciﬁcity 95% CI % prevalence PPV (%) NPV (%)
ES Symp 685 100 (71/71) 94.9–100 98.5 (605/614) 97.2–99.3 10.4 88.8 100
Asymp 1,114 98.1 (104/106) 93.4–99.8 99.1 (999/1,008) 98.3–99.6 9.5 92.0 99.8
Overall 1,799 98.9 (175/177) 96.0–99.9 98.9 (1,604/1,622) 98.3–99.3 9.8 90.7 99.9
P values 0.517 0.70, 4.48 0.331 1.69, 0.54
PC-VS Symp 682 98.6 (73/74) 92.7–100 99.5 (605/608) 98.6–99.9 10.9 96.1 99.8
Asymp 1,109 95.0 (113/119) 89.3–98.1 99.6 (986/990) 99.0–99.9 10.7 96.6 99.4
Overall 1,791 96.4 (186/193) 92.7–98.5 99.6 (1,591/1,598) 99.1–99.8 10.8 96.4 99.6
P values 0.254 1.04, 8.42 1.000 0.77, 0.59
UR Symp 688 98.6 (71/72) 92.5–100 99.8 (615/616) 99.1–100 10.5 98.6 99.8
Asymp 1,105 98.2 (109/111) 93.6–99.8 99.6 (990/994) 99.0–99.9 10.0 96.5 99.8
Overall 1,793 98.4 (180/183) 95.3–99.7 99.7 (1,605/1,610) 99.3–99.9 10.2 97.3 99.8
P values 1.000 3.25, 4.08 0.655 0.27, 0.75
aValues in parentheses are the number of true positives over the total of true positives plus false negatives (sensitivity) and the number of true negatives over the
total of true negatives plus false positives (speciﬁcity). PIS, patient infected status; PPV, positive predictive value; NPV, negative predictive value; ES, endocervical
swab; PC-VS, patient-collected vaginal swab; UR, urine; Symp, symptomatic; Asymp, asymptomatic.
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upper CI includes the null hypothesis, the sample size was too small for meaningful
analysis. Some site-to-site variation can be expected, as well as some amount of
sampling variation. Keeping this site in the pooled analysis, although it may have a
slightly lower sensitivity than the other sites, was considered conservative.
Results for male subjects. The data in Fig. 1 illustrate specimen accountability for
male subjects. A total of 4,798 male subjects were enrolled in the study, of whom 4,791
(99.9%) were eligible for evaluation. The seven ineligible subjects consisted of one
subject with improper or incomplete informed consent, two subjects previously en-
rolled in the study, two subjects who had been treated with antibiotics within the 21
days prior to study enrollment, one subject who was not sexually active, and one
subject14 years of age. The average age among eligible male study participants with
valid test results was 36.2 years (range, 16 to 78 years). Of these 4,611 study partici-
pants, 1,088 (23.6%) were symptomatic and 3,523 (76.5%) were asymptomatic. The
prevalence of T. vaginalis in males across all study sites was 2.7%.
In all, a total of 4,626 (96.6%) specimens from eligible male subjects were tested
using the Xpert TV assay. The urine specimens excluded consisted of 96 for shipping
delays, 36 tested 72 h after collection, 21 GeneXpert modules out of calibration, and
12 not tested. Xpert TV assays for 97.7% (4,521/4,626) of the samples from eligible
subjects were successful on the ﬁrst attempt. The 105 indeterminate results included 84
ERROR readouts, 12 INVALID readouts, and 9 NO RESULT readouts. One hundred of the
105 (95.2%) indeterminate cases were retested; 5 samples were not retested. Ninety of
100 (90%) indeterminate cases that were retested yielded valid results upon repeat
assay. Thus, the overall rate of Xpert TV assay success was 99.7% (4,611/4,626).
Overall, relative to the PIS results, the Xpert TV assay demonstrated initial diagnostic
sensitivity and speciﬁcity for male urine specimens of 89.6% and 99.3%, respectively
(Table 3). Secondary sequencing was performed on specimens with discordant results.
The validated bidirectional sequencing procedure demonstrated that the sequencing
limit of detection (LOD) was similar to the Xpert TV assay male urine analytical LOD,
resulting in similar frequencies of random dropouts for specimens with low levels of T.
vaginalis organisms. There were no statistically signiﬁcant differences in performance
with respect to symptomatic status.
DISCUSSION
Trichomoniasis is a highly prevalent STD and presents with a spectrum of symptoms
or with no symptoms (3). In women, the prevalence of infection spans the reproductive
years and beyond, with some studies showing high rates in older women (13). The
epidemiology is less well understood in men, although a recent study showed that age
over 40 years was also associated with T. vaginalis-associated sexually transmitted
infections (STIs) (14). Accurate identiﬁcation of trichomoniasis is important for several
reasons, including optimizing treatment, realizing the need for treatment of the sexual
partner(s) (15), and the potential for prevention of associated public health conse-
quences, such as preterm birth and the acquisition and transmission of HIV (6–8). The
CDC has recently recommended NAAT as the preferred diagnostic modality in light of
their superior sensitivity compared to those of direct microscopy or culture-based
TABLE 3 Xpert TV results versus PIS initial results based on symptomatic status for malesa
Status
No. of UR samples
tested Sensitivity 95% CI Speciﬁcity 95% CI % prevalence PPV (%) NPV (%)
Symp 1,088 87.5 (28/32) 71.9–95.0 99.8 (1,054/1,056) 99.3–99.9 2.9 93.3 99.6
Asymp 3,523 90.3 (84/93) 82.6–94.8 99.2 (3,401/3,430) 98.8–99.4 2.6 74.3 99.7
Total 4,611 89.6 (112/125)b 83.0–93.8 99.3 (4,455/4,486)c 99.0–99.5 2.7 78.3 99.7
P values 0.738 15.8, 10.1 0.020 0.25, 1.06
aValues in parentheses are the number of true positives over the total of true positives plus false negatives (sensitivity) and the number of true negatives over the
total of true negatives plus false positives (speciﬁcity). PIS, patient infected status; UR, urine; PPV, positive predictive value; NPV, negative predictive value; Symp,
symptomatic; Asymp, asymptomatic.
bResults from secondary sequencing: 9 of 13 false negatives were T. vaginalis negative and 4 of 13 were T. vaginalis positive.
cResults from secondary sequencing: 27 of 31 false positives were T. vaginalis positive and 4 of 31 were T. vaginalis negative.
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methods for detecting T. vaginalis (2). Diagnostic testing is recommended for symp-
tomatic women, and screening should be considered for individuals with multiple sex
partners, persons who exchange sex for payment, use drugs, and/or have a history of
STDs, and women in high-prevalence settings, such as STD clinics and correctional
facilities (2). Annual screening is recommended for women with HIV infection due to
the high rates of T. vaginalis infection in this population (16). Rescreening is recom-
mended within 3 months of the initial diagnosis due to high recurrence rates (17).
Currently, there are no ﬁrm screening recommendations for men due to the fact that
an FDA-cleared test has only recently become available. However, men attending STD
clinics should be considered for screening (2). A recent study showed a prevalence rate
of nearly 10% among men attending an STD clinic in Birmingham, AL (14).
Although other NAAT in addition to the Xpert TV assay have also recently been FDA
cleared for the diagnosis of T. vaginalis in women (11, 18), the Xpert TV assay can
provide on-demand results in 63 min or less, with early termination for positive results
within 40 min. This quicker turnaround time makes the GeneXpert platform ideal for
use in high-risk settings where diagnosis and treatment could ideally take place in real
time for optimal public health control of this STD.
The platform is easy to use and, thus, suitable for in-clinic testing at the point of care
(POC). Furthermore, the equally high diagnostic sensitivities and speciﬁcities demon-
strated here for urine, self-collected vaginal swabs, and endocervical swabs in symp-
tomatic and asymptomatic patients make the assay an important diagnostic screening
tool for patients in high-risk settings like STI clinics and emergency departments, as well
as gynecology clinics with laboratory facilities. Of note, the majority of men were
asymptomatic, suggesting that screening for trichomoniasis should be considered for
high-risk men, such as those attending STD clinics.
The availability of NAAT testing for T. vaginalis in men is a welcome addition from
a public health perspective and has been a key element missing for the control of this
STD. The sensitivity and speciﬁcity of the Xpert TV assay relative to the PIS results were
both high, 97.2% and 99.9%, respectively. However, it should be noted that InPouch
cultures for this study followed the current manufacturer’s package insert at the time
of the study (Biomed Diagnostics document no. 100-001, revision K), which instructed
users to incubate and read cultures for up to 3 days. A study conducted by Rivers and
colleagues (19) showed that an additional 17.2% of cultures were identiﬁed as positive
when cultures were incubated and read up for to 5 days. Thus, a study comparing the
Xpert TV assay directly to InPouch cultures incubated for 5 days would need to be
conducted in order to determine whether the sensitivity of the Xpert assay would be
slightly lower.
In summary, T. vaginalis is a highly prevalent STI associated with increased risk of HIV
acquisition and transmission, as well as preterm births. The availability of an FDA-
cleared test for men is especially welcome. Recent advances in molecular diagnostics
for this highly prevalent infection, if implemented, should begin to reduce the burden
of disease.
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